Login to Your Account

Wuxi, Lilly unite on CV-targeting small molecule for China

By Shannon Ellis
Staff Writer

Friday, November 13, 2015

SHANGHAI – For the second time this year, Eli Lilly and Co. entered a strategic collaboration agreement with a local Chinese company to co-develop a novel candidate for the China market, this time with Shanghai-based Wuxi Pharmatech (Cayman) Inc., the well-respected, multifunctional contract research organization (CRO) and contract manufacturer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription